Citations

Mayo Clinic

Clear

389 citation(s) found for "Ailawadhi, Sikander".

Molecular architecture simulation and reverse engineering techniques to uncover clinically applicable novel therapeutic targets in B-lymphoma cells.
Paulus, Aneel , Kumar, Ansu, Singh, Neeraj Kumar , Vali, Shireen, Abbasi, Taher, Chanan‐Khan, Asher , Paulus, Aneel , Akhtar, Sharoon , Singh, Neeraj Kumar , Ailawadhi, Sikander

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e23169-e23169

10.1200/jco.2016.34.15_suppl.e23169 Get It

Patterns of palliative care utilization in stage IV non-small cell lung cancer in the National Cancer Database.
Duma, Narjust , Frank, Ryan D. , Yadav, Siddhartha , Molina, Julian R. , Moynihan, Timothy J. , Yadav, Siddhartha , Durani, Urshila , Goyal, Gaurav , Mansfield, Aaron S. , Ailawadhi, Sikander , Go, Ronald S.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10109-10109

10.1200/jco.2018.36.15_suppl.10109 Get It

Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): A SEER-Medicare analysis.
Parikh, Kejal , Clancy, Zoe, Zhou, Zheng‐Yi , Cheung, Claudia , Zhou, Zhou , Xie, Jipan , Tang, Wenxi , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20030-e20030

10.1200/jco.2018.36.15_suppl.e20030 Get It

Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.
Rifkin, Robert M. , Gasparetto, Cristina, Toomey, Kathleen, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Srinivasan, Shankar , YoussefAgha, Ahmed, Ung, Brian , Kitali, Amani, Flick, E. Dawn, Agarwal, Amit , Abonour, Rafat , Jagannath, Sundar , Gasparetto, Cristina , Hardin, James W. , Wagner, Lynne I. , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8041-8041

10.1200/jco.2018.36.15_suppl.8041 Get It

Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.
Gasparetto, Cristina, Rifkin, Robert M. , Terebelo, Howard R. , Toomey, Kathleen, Durie, Brian G.M. , Narang, Mohit , Flick, E. Dawn, Kotey, Stanley, Srinivasan, Shankar , Kitali, Amani, Agarwal, Amit , Abonour, Rafat , Gasparetto, Cristina , Hardin, James W. , Jagannath, Sundar , Wagner, Lynne I. , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8037-8037

10.1200/jco.2018.36.15_suppl.8037 Get It

CD38-targeted therapy in glioblastoma: A step forward.
Paulus, Aneel , Rosenfeld, Steven S. , Chanan‐Khan, Asher , Quiñones‐Hinojosa, Alfredo , Paulus, Aneel , Aulakh, Sonikpreet , Manna, Alak , Schiapparelli, Paula , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e14030-e14030

10.1200/jco.2018.36.15_suppl.e14030 Get It

Association between treatment facility volume and mortality in patients with glioblastoma (GBM): A large national analysis.
DeDeo, Michelle , Free, Joseph, Berdeguez, Kyle, Rosenfeld, Steven S. , Quiñones‐Hinojosa, Alfredo , Chanan‐Khan, Asher , Aulakh, Sonikpreet , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2026-2026

10.1200/jco.2018.36.15_suppl.2026 Get It

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).
Holstein, Sarah A. , Larkins, Gail, Chung, Weiyuan, Srinivasan, Shankar , Agarwal, Amit , Ailawadhi, Sikander , McCarthy, Philip L. , Lonial, Sagar

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8050-8050

10.1200/jco.2018.36.15_suppl.8050 Get It

Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.
Sexton, Rachael, Lentzsch, Suzanne , Voorhees, Peter M. , Rohren, Eric , Kelly, Kevin R. , Mackler, Niklas J., Baer, David, Hoering, Antje , Durie, Brian G.M. , Ailawadhi, Sikander , Abidi, Muneer H. , Cohen, Adam D. , Heitner, Stephen B. , Orlowski, Robert Z.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8015-8015

10.1200/jco.2018.36.15_suppl.8015 Get It

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
Lou, Yanyan , Dholaria, Bhagirathbhai , Soyano, Aixa , Hodge, David O. , Cochuyt, Jordan J., Thomas, Mathew , Johnson, Margaret M. , Patel, Neal M. , Miller, Robert C. , Adjei, Alex A. , Hodge, David, Cochuyt, Jordan, Manochakian, Rami , Ko, Stephen J. , Ailawadhi, Sikander , Thomas, Mathew , Dholaria, Bhagirathbhai R , Soyano, Aixa , Ailawadhi, Sikander

Cancer Medicine | September 2, 2018 | Volume: 7 | Issue: 10 | Pages: 4932-4942

10.1002/cam4.1749 | PMID 30175515 Get It

Abstract Background Treatment of non‐small‐cell lung cancer (NSCLC) has been rapidly advancing over the last decade. Academic centers are considered equipped with better expertise. NSCLC outcome trends in novel therapeutic era and impact of initial treatment at academic centers have not been reported. Methods The National Cancer Database (NCDB) was used to identify NSCLC incident cases from 2004 to 2013. Overall survival (OS) was plotted by year of diagnosis and type of initial treatment center, accounting for several factors available in NCDB. Results A total of 1 150 722 NSCLC patients were included and separated by initial treatment center type (academic: 31.5%; nonacademic: 68.5%). Median follow‐up and OS for all patients were 11.8 months (range: 0‐133.6 months) and 13.1 months (95% CI: 13.08‐13.17), respectively. Median OS improved significantly for those diagnosed in 2010‐2013 (14.8 months [95% CI: 14.7‐14.9]) as compared to 2004‐2009 (12.4 months [95% CI: 12.3‐12.5]) ( P < 0.001). Treatment at academic centers was associated with improved OS (multivariate HR for OS = 0.929 [95% CI: 0.92‐0.94], P < 0.0010). Four‐year OS for academic and nonacademic cohorts was 28.5%% and 22.1%, respectively ( P < 0.001), and the difference was more pronounced in stage I to III NSCLC. Conclusion In this largest analysis, thus far, NSCLC survival has improved over time, and type of initial treatment center significantly influences survival. Identifying and removing barriers to obtaining initial treatment of NSCLC at academic medical centers could improve OS.